Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can Vivus Get Away Without Outcomes Study Of Obesity Drug Qsymia?

Jan 16 2019

• By Emily Hayes

Fat sad man and his reflection in the mirror of a normal man against sky. Obesity concept - Illustration

Related Content

CAMELLIA Adds To Belviq’s CV Confidence But ‘Caution’ Still Needed

Aug 28 2018

FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients

Jul 18 2012

Panel Favors Qnexa Approval, Given Strong Efficacy, Certainty Of Post-Approval CV Study

Feb 22 2012

Is Vivus worth saving?

Aug 01 2015

If Orexigen Disappears, Who's Left In The Obesity Market?

Oct 18 2017

Related Companies

Vivus, Inc.

Eisai Co., Ltd.

Arena Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Safety FDA Research & Development Cardiovascular BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window